TRDA — Entrada Therapeutics Balance Sheet
0.000.00%
- $481.07m
- $153.65m
- $129.01m
- 61
- 63
- 79
- 76
Annual balance sheet for Entrada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 16.8 | 39 | 291 | 189 | 352 |
Net Total Receivables | — | — | — | — | 5.88 |
Prepaid Expenses | |||||
Total Current Assets | 17.4 | 39.9 | 299 | 210 | 370 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.801 | 3.04 | 6.26 | 33 | 92.7 |
Other Long Term Assets | |||||
Total Assets | 18.2 | 43.5 | 306 | 252 | 469 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.92 | 3.36 | 6.72 | 22 | 159 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.94 | 3.36 | 7.12 | 39.5 | 227 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 16.3 | 40.2 | 299 | 213 | 242 |
Total Liabilities & Shareholders' Equity | 18.2 | 43.5 | 306 | 252 | 469 |
Total Common Shares Outstanding |